<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2022v5.0">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2023-11-01T14:47:55-05:00</ReturnTs>
    <TaxPeriodEndDt>2022-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>042571780</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>AAFCPAS INC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>50 WASHINGTON STREET</AddressLine1Txt>
        <CityNm>WESTBOROUGH</CityNm>
        <StateAbbreviationCd>MA</StateAbbreviationCd>
        <ZIPCd>01581</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990PF</ReturnTypeCd>
    <TaxPeriodBeginDt>2022-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>043507847</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>CHARLES H HOOD FOUNDATION</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>CHAR</BusinessNameControlTxt>
      <PhoneNum>6172792230</PhoneNum>
      <USAddress>
        <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
        <CityNm>BOSTON</CityNm>
        <StateAbbreviationCd>MA</StateAbbreviationCd>
        <ZIPCd>02116</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>NEIL SMILEY</PersonNm>
      <PersonTitleTxt>PRESIDENT AND TREASURER</PersonTitleTxt>
      <PhoneNum>6172792230</PhoneNum>
      <SignatureDt>2023-10-24</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>NEIL</PersonFirstNm>
        <PersonLastNm>SMILEY</PersonLastNm>
      </PersonFullName>
      <SSN>XXX-XX-XXXX</SSN>
    </SigningOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>1</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>JOYCE RIPIANZI CPA</PreparerPersonNm>
      <PTIN>P00548581</PTIN>
      <PhoneNum>5083669100</PhoneNum>
      <PreparationDt>2023-10-24</PreparationDt>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>2</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2022</TaxYr>
    <BuildTS>2023-04-26 12:10:37Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="15">
    <IRS990PF documentId="RetDoc1235000001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <FMVAssetsEOYAmt>66678123</FMVAssetsEOYAmt>
      <MethodOfAccountingCashInd>X</MethodOfAccountingCashInd>
      <AnalysisOfRevenueAndExpenses>
        <ContriRcvdRevAndExpnssAmt>1029761</ContriRcvdRevAndExpnssAmt>
        <DividendsRevAndExpnssAmt>1335080</DividendsRevAndExpnssAmt>
        <DividendsNetInvstIncmAmt>1335080</DividendsNetInvstIncmAmt>
        <NetGainSaleAstRevAndExpnssAmt>612940</NetGainSaleAstRevAndExpnssAmt>
        <GrossSalesPriceAmt>3183933</GrossSalesPriceAmt>
        <CapGainNetIncmNetInvstIncmAmt>612940</CapGainNetIncmNetInvstIncmAmt>
        <IncmModificationsAdjNetIncmAmt>31917</IncmModificationsAdjNetIncmAmt>
        <OtherIncomeRevAndExpnssAmt referenceDocumentId="RetDoc2001500001">37260</OtherIncomeRevAndExpnssAmt>
        <OtherIncomeNetInvstIncmAmt>0</OtherIncomeNetInvstIncmAmt>
        <TotalRevAndExpnssAmt>3015041</TotalRevAndExpnssAmt>
        <TotalNetInvstIncmAmt>1948020</TotalNetInvstIncmAmt>
        <TotalAdjNetIncmAmt>31917</TotalAdjNetIncmAmt>
        <CompOfcrDirTrstRevAndExpnssAmt>0</CompOfcrDirTrstRevAndExpnssAmt>
        <CompOfcrDirTrstNetInvstIncmAmt>0</CompOfcrDirTrstNetInvstIncmAmt>
        <CompOfcrDirTrstDsbrsChrtblAmt>0</CompOfcrDirTrstDsbrsChrtblAmt>
        <LegalFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002100001">30210</LegalFeesRevAndExpnssAmt>
        <LegalFeesNetInvstIncmAmt>0</LegalFeesNetInvstIncmAmt>
        <LegalFeesDsbrsChrtblAmt>30210</LegalFeesDsbrsChrtblAmt>
        <AccountingFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002200001">26003</AccountingFeesRevAndExpnssAmt>
        <AccountingFeesNetInvstIncmAmt>0</AccountingFeesNetInvstIncmAmt>
        <AccountingFeesChrtblPrpsAmt>26003</AccountingFeesChrtblPrpsAmt>
        <OtherProfFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002300001">103585</OtherProfFeesRevAndExpnssAmt>
        <OtherProfFeesNetInvstIncmAmt>89292</OtherProfFeesNetInvstIncmAmt>
        <OtherProfFeesDsbrsChrtblAmt>14293</OtherProfFeesDsbrsChrtblAmt>
        <TaxesRevAndExpnssAmt referenceDocumentId="RetDoc2002500001">83679</TaxesRevAndExpnssAmt>
        <TaxesNetInvstIncmAmt>25400</TaxesNetInvstIncmAmt>
        <TaxesDsbrsChrtblAmt>500</TaxesDsbrsChrtblAmt>
        <TravConfMeetingRevAndExpnssAmt>23125</TravConfMeetingRevAndExpnssAmt>
        <TravConfMeetingNetInvstIncmAmt>0</TravConfMeetingNetInvstIncmAmt>
        <TravConfMeetingDsbrsChrtblAmt>23125</TravConfMeetingDsbrsChrtblAmt>
        <OtherExpensesRevAndExpnssAmt referenceDocumentId="RetDoc2003200001">398201</OtherExpensesRevAndExpnssAmt>
        <OtherExpensesNetInvstIncmAmt>0</OtherExpensesNetInvstIncmAmt>
        <OtherExpensesDsbrsChrtblAmt>398201</OtherExpensesDsbrsChrtblAmt>
        <TotOprExpensesRevAndExpnssAmt>664803</TotOprExpensesRevAndExpnssAmt>
        <TotOprExpensesNetInvstIncmAmt>114692</TotOprExpensesNetInvstIncmAmt>
        <TotOprExpensesDsbrsChrtblAmt>492332</TotOprExpensesDsbrsChrtblAmt>
        <ContriPaidRevAndExpnssAmt>2662000</ContriPaidRevAndExpnssAmt>
        <ContriPaidDsbrsChrtblAmt>2662000</ContriPaidDsbrsChrtblAmt>
        <TotalExpensesRevAndExpnssAmt>3326803</TotalExpensesRevAndExpnssAmt>
        <TotalExpensesNetInvstIncmAmt>114692</TotalExpensesNetInvstIncmAmt>
        <TotalExpensesDsbrsChrtblAmt>3154332</TotalExpensesDsbrsChrtblAmt>
        <ExcessRevenueOverExpensesAmt>-311762</ExcessRevenueOverExpensesAmt>
        <NetInvestmentIncomeAmt>1833328</NetInvestmentIncomeAmt>
        <AdjustedNetIncomeAmt>31917</AdjustedNetIncomeAmt>
      </AnalysisOfRevenueAndExpenses>
      <Form990PFBalanceSheetsGrp>
        <SavAndTempCashInvstBOYAmt>679672</SavAndTempCashInvstBOYAmt>
        <SavAndTempCashInvstEOYAmt>383193</SavAndTempCashInvstEOYAmt>
        <SavAndTempCashInvstEOYFMVAmt>383193</SavAndTempCashInvstEOYFMVAmt>
        <CorporateStockBOYAmt>45446070</CorporateStockBOYAmt>
        <CorporateStockEOYAmt referenceDocumentId="RetDoc2018900001">34837751</CorporateStockEOYAmt>
        <CorporateStockEOYFMVAmt>34837751</CorporateStockEOYFMVAmt>
        <CorporateBondsBOYAmt>17200112</CorporateBondsBOYAmt>
        <CorporateBondsEOYAmt referenceDocumentId="RetDoc2044400001">13292160</CorporateBondsEOYAmt>
        <CorporateBondsEOYFMVAmt>13292160</CorporateBondsEOYFMVAmt>
        <OtherInvestmentsBOYAmt>13066723</OtherInvestmentsBOYAmt>
        <OtherInvestmentsEOYAmt referenceDocumentId="RetDoc2018100001">14795058</OtherInvestmentsEOYAmt>
        <OtherInvestmentsEOYFMVAmt>14795058</OtherInvestmentsEOYFMVAmt>
        <OtherAssetsBOYAmt referenceDocumentId="RetDoc2046600001">2569964</OtherAssetsBOYAmt>
        <OtherAssetsEOYAmt referenceDocumentId="RetDoc2046600001">3369961</OtherAssetsEOYAmt>
        <OtherAssetsEOYFMVAmt referenceDocumentId="RetDoc2046600001">3369961</OtherAssetsEOYFMVAmt>
        <TotalAssetsBOYAmt>78962541</TotalAssetsBOYAmt>
        <TotalAssetsEOYAmt>66678123</TotalAssetsEOYAmt>
        <TotalAssetsEOYFMVAmt>66678123</TotalAssetsEOYFMVAmt>
        <TotalLiabilitiesBOYAmt>0</TotalLiabilitiesBOYAmt>
        <TotalLiabilitiesEOYAmt>0</TotalLiabilitiesEOYAmt>
        <OrgDoesNotFollowFASB117Ind>X</OrgDoesNotFollowFASB117Ind>
        <CapitalStockBOYAmt>59300755</CapitalStockBOYAmt>
        <CapitalStockEOYAmt>59300755</CapitalStockEOYAmt>
        <AdditionalPaidInCapitalBOYAmt>0</AdditionalPaidInCapitalBOYAmt>
        <AdditionalPaidInCapitalEOYAmt>0</AdditionalPaidInCapitalEOYAmt>
        <RetainedEarningBOYAmt>19661786</RetainedEarningBOYAmt>
        <RetainedEarningEOYAmt>7377368</RetainedEarningEOYAmt>
        <TotNetAstOrFundBalancesBOYAmt>78962541</TotNetAstOrFundBalancesBOYAmt>
        <TotNetAstOrFundBalancesEOYAmt>66678123</TotNetAstOrFundBalancesEOYAmt>
        <TotalLiabilitiesNetAstBOYAmt>78962541</TotalLiabilitiesNetAstBOYAmt>
        <TotalLiabilitiesNetAstEOYAmt>66678123</TotalLiabilitiesNetAstEOYAmt>
      </Form990PFBalanceSheetsGrp>
      <ChgInNetAssetsFundBalancesGrp>
        <TotNetAstOrFundBalancesBOYAmt>78962541</TotNetAstOrFundBalancesBOYAmt>
        <ExcessRevenueOverExpensesAmt>-311762</ExcessRevenueOverExpensesAmt>
        <OtherIncreasesAmt>0</OtherIncreasesAmt>
        <SubtotalAmt>78650779</SubtotalAmt>
        <OtherDecreasesAmt referenceDocumentId="RetDoc2049800001">11972656</OtherDecreasesAmt>
        <TotNetAstOrFundBalancesEOYAmt>66678123</TotNetAstOrFundBalancesEOYAmt>
      </ChgInNetAssetsFundBalancesGrp>
      <CapGainsLossTxInvstIncmDetail>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>PUBLICLY TRADED SECURITIES</PropertyDesc>
          <GrossSalesPriceAmt>2816232</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>2570993</CostOrOtherBasisAmt>
          <GainOrLossAmt>245239</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>245239</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>CAPITAL GAINS DIVIDENDS</PropertyDesc>
          <HowAcquiredCd>P</HowAcquiredCd>
          <GrossSalesPriceAmt>367701</GrossSalesPriceAmt>
          <GainOrLossAmt>367701</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>367701</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapitalGainNetIncomeAmt>612940</CapitalGainNetIncomeAmt>
      </CapGainsLossTxInvstIncmDetail>
      <ExciseTaxBasedOnInvstIncmGrp>
        <InvestmentIncomeExciseTaxAmt>25483</InvestmentIncomeExciseTaxAmt>
        <TaxUnderSection511Amt>0</TaxUnderSection511Amt>
        <SubtotalAmt>25483</SubtotalAmt>
        <SubtitleATaxAmt>0</SubtitleATaxAmt>
        <TaxBasedOnInvestmentIncomeAmt>25483</TaxBasedOnInvestmentIncomeAmt>
        <EstimatedPlusOvpmtIncmTxAmt>47510</EstimatedPlusOvpmtIncmTxAmt>
        <ExemptFrgnOrgTaxWthldAtSrceAmt>0</ExemptFrgnOrgTaxWthldAtSrceAmt>
        <ExtsnRequestIncomeTaxPaidAmt>0</ExtsnRequestIncomeTaxPaidAmt>
        <BackupWithholdingWithheldAmt>0</BackupWithholdingWithheldAmt>
        <TotalPaymentsAndCreditsAmt>47510</TotalPaymentsAndCreditsAmt>
        <EsPenaltyAmt>0</EsPenaltyAmt>
        <OverpaymentAmt>22027</OverpaymentAmt>
        <AppliedToESTaxAmt>22027</AppliedToESTaxAmt>
        <RefundAmt>0</RefundAmt>
      </ExciseTaxBasedOnInvstIncmGrp>
      <StatementsRegardingActyGrp>
        <LegislativePoliticalActyInd>0</LegislativePoliticalActyInd>
        <MoreThan100SpentInd>0</MoreThan100SpentInd>
        <Form1120POLFiledInd>0</Form1120POLFiledInd>
        <Section4955OrganizationTaxAmt>0</Section4955OrganizationTaxAmt>
        <Section4955ManagersTaxAmt>0</Section4955ManagersTaxAmt>
        <TaxReimbursedAmt>0</TaxReimbursedAmt>
        <ActivitiesNotPreviouslyRptInd>0</ActivitiesNotPreviouslyRptInd>
        <ChangesToArticlesOrBylawsInd>0</ChangesToArticlesOrBylawsInd>
        <UnrelatedBusIncmOverLimitInd>1</UnrelatedBusIncmOverLimitInd>
        <Form990TFiledInd>1</Form990TFiledInd>
        <OrganizationDissolvedEtcInd>0</OrganizationDissolvedEtcInd>
        <Section508eRqrSatisfiedInd>1</Section508eRqrSatisfiedInd>
        <AtLeast5000InAssetsInd>1</AtLeast5000InAssetsInd>
        <OrgReportOrRegisterStateCd>MA</OrgReportOrRegisterStateCd>
        <Form990PFFiledWithAttyGenInd>1</Form990PFFiledWithAttyGenInd>
        <PrivateOperatingFoundationInd>0</PrivateOperatingFoundationInd>
        <NewSubstantialContributorsInd>0</NewSubstantialContributorsInd>
        <OwnControlledEntityInd>1</OwnControlledEntityInd>
        <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
        <ComplyWithPublicInspRqrInd>1</ComplyWithPublicInspRqrInd>
        <WebsiteAddressTxt>HTTPS://HRIA.ORG/TMF/HOOD/</WebsiteAddressTxt>
        <IndividualWithBooksNm>AAFCPAS INC</IndividualWithBooksNm>
        <PhoneNum>5083669100</PhoneNum>
        <LocationOfBooksUSAddress>
          <AddressLine1Txt>50 WASHINGTON STREET</AddressLine1Txt>
          <CityNm>WESTBOROUGH</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01581</ZIPCd>
        </LocationOfBooksUSAddress>
        <ForeignAccountsQuestionInd>0</ForeignAccountsQuestionInd>
      </StatementsRegardingActyGrp>
      <StatementsRegardingActy4720Grp>
        <SaleOrExchDisqualifiedPrsnInd>0</SaleOrExchDisqualifiedPrsnInd>
        <BrrwOrLendDisqualifiedPrsnInd>0</BrrwOrLendDisqualifiedPrsnInd>
        <FurnGoodsDisqualifiedPrsnInd>0</FurnGoodsDisqualifiedPrsnInd>
        <PayCompDisqualifiedPrsnInd>1</PayCompDisqualifiedPrsnInd>
        <TransferAstDisqualifiedPrsnInd>0</TransferAstDisqualifiedPrsnInd>
        <PaymentToGovernmentOfficialInd>0</PaymentToGovernmentOfficialInd>
        <ActsFailToQlfyAsExceptionsInd>0</ActsFailToQlfyAsExceptionsInd>
        <UncorrectedPriorActsInd>0</UncorrectedPriorActsInd>
        <UndistributedIncomePYInd>0</UndistributedIncomePYInd>
        <BusinessHoldingsInd>1</BusinessHoldingsInd>
        <ExcessBusinessHoldingsInd>0</ExcessBusinessHoldingsInd>
        <JeopardyInvestmentsInd>0</JeopardyInvestmentsInd>
        <UncorrectedPYJeopardyInvstInd>0</UncorrectedPYJeopardyInvstInd>
        <InfluenceLegislationInd>0</InfluenceLegislationInd>
        <InfluenceElectionInd>0</InfluenceElectionInd>
        <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
        <GrantsToOrganizationsInd>1</GrantsToOrganizationsInd>
        <NoncharitablePurposeInd>0</NoncharitablePurposeInd>
        <TransactionsFailToQlfyAsExcInd>0</TransactionsFailToQlfyAsExcInd>
        <MaintainedExpenditureRspnsInd referenceDocumentId="RetDoc2118100001">1</MaintainedExpenditureRspnsInd>
        <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
        <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
        <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
        <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      </StatementsRegardingActy4720Grp>
      <OfficerDirTrstKeyEmplInfoGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>NEIL SMILEY</PersonNm>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <TitleTxt>PRESIDENT AND TREASURER</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>JOHN O PARKER JR</PersonNm>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <TitleTxt>VICE PRESIDENT AND CLERK</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ROBERT C BOUTWELL</PersonNm>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>BARBARA BULA</PersonNm>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>BRENDON BULA</PersonNm>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ELIZABETH HOOD</PersonNm>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>CLAY SMILEY</PersonNm>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <TitleTxt>TRUSTEE</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>1.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <CompOfHghstPdEmplOrNONETxt>NONE</CompOfHghstPdEmplOrNONETxt>
        <OtherEmployeePaidOver50kCnt>0</OtherEmployeePaidOver50kCnt>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>HEALTH RESOURCES IN ACTION</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>ADMINISTRATIVE FEES</ServiceTypeTxt>
          <CompensationAmt>199378</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <CompensationOfHghstPdCntrctGrp>
          <BusinessName>
            <BusinessNameLine1Txt>PRIME BUCHHOLZ</BusinessNameLine1Txt>
          </BusinessName>
          <USAddress>
            <AddressLine1Txt>273 CORPORATE DRIVE SUITE 250</AddressLine1Txt>
            <CityNm>PORTSMOUTH</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>03801</ZIPCd>
          </USAddress>
          <ServiceTypeTxt>INVESTMENT ADVISORY SERVICES</ServiceTypeTxt>
          <CompensationAmt>75000</CompensationAmt>
        </CompensationOfHghstPdCntrctGrp>
        <ContractorPaidOver50kCnt>0</ContractorPaidOver50kCnt>
      </OfficerDirTrstKeyEmplInfoGrp>
      <SumOfProgramRelatedInvstGrp>
        <Description1Txt>INKSPACE IMAGING, INC. - PLEASANTON, CACONVERTIBLE PROMISSORY NOTE</Description1Txt>
        <Expenses1Amt>250000</Expenses1Amt>
        <Description2Txt>DECK THERAPEUTICS, INC. - HUDSON, NY SAFE - SIMPLE AGREEMENT FOR FUTURE EQUITY</Description2Txt>
        <Expenses2Amt>200000</Expenses2Amt>
        <AllOtherProgramRltdInvstTotAmt referenceDocumentId="RetDoc2063500001">349997</AllOtherProgramRltdInvstTotAmt>
        <TotalAmt>799997</TotalAmt>
      </SumOfProgramRelatedInvstGrp>
      <MinimumInvestmentReturnGrp>
        <AverageMonthlyFMVOfSecAmt>55574961</AverageMonthlyFMVOfSecAmt>
        <AverageMonthlyCashBalancesAmt>377542</AverageMonthlyCashBalancesAmt>
        <FMVAllOtherNoncharitableAstAmt>12208432</FMVAllOtherNoncharitableAstAmt>
        <TotalFMVOfUnusedAssetsAmt>68160935</TotalFMVOfUnusedAssetsAmt>
        <ReductionClaimedAmt>0</ReductionClaimedAmt>
        <AcquisitionIndebtednessAmt>0</AcquisitionIndebtednessAmt>
        <AdjustedTotalFMVOfUnusedAstAmt>68160935</AdjustedTotalFMVOfUnusedAstAmt>
        <CashDeemedCharitableAmt>1022414</CashDeemedCharitableAmt>
        <NetVlNoncharitableAssetsAmt>67138521</NetVlNoncharitableAssetsAmt>
        <MinimumInvestmentReturnAmt>3356926</MinimumInvestmentReturnAmt>
      </MinimumInvestmentReturnGrp>
      <DistributableAmountGrp>
        <MinimumInvestmentReturnAmt>3356926</MinimumInvestmentReturnAmt>
        <TaxBasedOnInvestmentIncomeAmt>25483</TaxBasedOnInvestmentIncomeAmt>
        <TotalTaxAmt>25483</TotalTaxAmt>
        <DistributableBeforeAdjAmt>3331443</DistributableBeforeAdjAmt>
        <RecoveriesQualfiedDistriAmt>31917</RecoveriesQualfiedDistriAmt>
        <DistributableBeforeDedAmt>3363360</DistributableBeforeDedAmt>
        <DeductionFromDistributableAmt>0</DeductionFromDistributableAmt>
        <DistributableAsAdjustedAmt>3363360</DistributableAsAdjustedAmt>
      </DistributableAmountGrp>
      <PFQualifyingDistributionsGrp>
        <ExpensesAndContributionsAmt>3154332</ExpensesAndContributionsAmt>
        <ProgramRelatedInvstTotalAmt>799997</ProgramRelatedInvstTotalAmt>
        <QualifyingDistributionsAmt>3954329</QualifyingDistributionsAmt>
      </PFQualifyingDistributionsGrp>
      <UndistributedIncomeGrp>
        <DistributableAsAdjustedAmt>3363360</DistributableAsAdjustedAmt>
        <UndistributedIncomePYAmt>3892877</UndistributedIncomePYAmt>
        <TotalForPriorYearsAmt>0</TotalForPriorYearsAmt>
        <TotalExcessDistributionCyovAmt>0</TotalExcessDistributionCyovAmt>
        <QualifyingDistributionsAmt>3954329</QualifyingDistributionsAmt>
        <AppliedToYear1Amt>3892877</AppliedToYear1Amt>
        <AppliedToPriorYearsAmt>0</AppliedToPriorYearsAmt>
        <TreatedAsDistriFromCorpusAmt>0</TreatedAsDistriFromCorpusAmt>
        <AppliedToCurrentYearAmt>61452</AppliedToCurrentYearAmt>
        <RemainingDistriFromCorpusAmt>0</RemainingDistriFromCorpusAmt>
        <ExcessDistriCyovAppCYCorpusAmt>0</ExcessDistriCyovAppCYCorpusAmt>
        <ExcessDistributionCyovAppCYAmt>0</ExcessDistributionCyovAppCYAmt>
        <TotalCorpusAmt>0</TotalCorpusAmt>
        <PriorYearUndistributedIncmAmt>0</PriorYearUndistributedIncmAmt>
        <PriorYearDeficiencyOrTaxAmt>0</PriorYearDeficiencyOrTaxAmt>
        <Taxable1Amt>0</Taxable1Amt>
        <Taxable2Amt>0</Taxable2Amt>
        <UndistributedIncomeCYAmt>3301908</UndistributedIncomeCYAmt>
        <CorpusDistri170b1EOr4942g3Amt>0</CorpusDistri170b1EOr4942g3Amt>
        <ExcessDistriCyovFromYr5Amt>0</ExcessDistriCyovFromYr5Amt>
        <ExcessDistriCyovToNextYrAmt>0</ExcessDistriCyovToNextYrAmt>
      </UndistributedIncomeGrp>
      <SupplementaryInformationGrp>
        <ApplicationSubmissionInfoGrp>
          <RecipientPersonNm>CHARLENE MANCUSI DIRECTOR HRIA</RecipientPersonNm>
          <RecipientUSAddress>
            <AddressLine1Txt>2 BOYLSTON STREET 4TH FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02116</ZIPCd>
          </RecipientUSAddress>
          <RecipientPhoneNum>6176959439</RecipientPhoneNum>
          <RecipientEmailAddressTxt>CMANCUSI@HRIA.ORG</RecipientEmailAddressTxt>
          <FormAndInfoAndMaterialsTxt>APPLICATION FORMS AVAILABLE AT WWW.TMFGRANTS.ORG/HOOD</FormAndInfoAndMaterialsTxt>
          <SubmissionDeadlinesTxt>ANNUALLY MARCH AND OCTOBER</SubmissionDeadlinesTxt>
          <RestrictionsOnAwardsTxt>RESTRICTED TO PEDIATRIC RESEARCH</RestrictionsOnAwardsTxt>
        </ApplicationSubmissionInfoGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON MEDICAL CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>660 HARRISON AVENUE 2ND FLOOR</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02118</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAJOR GRANT - BEYOND WATCHING AND WAITING: A NOVEL COLLABORATION TO PREVENT AND REDUCE THE BURDEN OF MENTAL ILLNESS IN HIGH-RISK, UNDERSERVED YOUTH WITH EPILEPSY</GrantOrContributionPurposeTxt>
          <Amt>225000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF DARTMOUTH COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS 11</AddressLine1Txt>
            <AddressLine2Txt>ROPE FERRY ROAD</AddressLine2Txt>
            <CityNm>HANOVER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>037551421</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAJOR GRANT - DECREASING HARMS AND IMPROVING CHILD HEALTH: AN INTERVENTION TO REDUCE INAPPROPRIATE USE OF ANTIPSYCHOTICS AND POLYPHARMACY</GrantOrContributionPurposeTxt>
          <Amt>379750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 414413</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414413</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DYSREGULATED T AND B CELL INTERACTIONS IN EARLY-ONSET OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>DANA-FARBER CANCER INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>450 BROOKLINE AVE BP437</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155450</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - MACHINE LEARNING-BASED RISK PREDICTION FOR CHILDREN WITH MEDULLOBLASTOMA</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 1873</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065081873</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DYSREGULATED RNA MODIFICATIONS IN THE CONTEXT OF HUMAN DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA NA PO BOX</AddressLine1Txt>
            <AddressLine2Txt>414876</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022414876</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - ILLUMINATING THE FUNCTION OF POLYCYSTINS AS CILIARY MECHANOTRANSDUCERS IN LEFT-RIGHT AXIS DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 415649</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022415649</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - MATURATION OF THE UTERUS DURING PUBERTY</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 1873</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065081873</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - IDENTIFYING THE CELL OF ORIGIN IN INTESTINAL CYSTIC FIBROSIS DISEASE</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 LAKE AVENUE NORTH</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01655</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - UNDERSTANDING NEONATAL INDUCTION OF PROALLERGIC T FOLLICULAR HELPER CELLS</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 222 BROADWAY ST</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - THE ROLE OF MARCO IN PEDIATRIC CANCER</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - THE ROLE OF AIRWAY NEURONS IN CHILDHOOD ASTHMA</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DEVELOPING A BROADLY APPLICABLE THERAPEUTIC STRATEGY TO REVERSE SYMPTOMS OF NEURODEVELOPMENTAL DISORDERS</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 208239</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208239</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - NEURAL MARKERS OF CHRONIC, PERSISTENT PEDIATRIC IRRITABILITY</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - SPATIAL MAPPING OF MALIGNANT SUBPOPULATIONS ENABLING NEURON-GLIOMA CIRCUIT INTERACTIONS IN DIPG</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DISSECTING IMMUNE-STROMAL INTERACTIONS TO DISCOVER NOVEL STRATEGY TO MODULATE INFLAMMATION</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - THE ROLE AND MECHANISM OF MAKORIN RING FINGER PROTEIN 3 IN CHILDREN WITH DELAYED PUBERTY</GrantOrContributionPurposeTxt>
          <Amt>160000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 1295 BOYLSTON</AddressLine1Txt>
            <AddressLine2Txt>STREET 4TH FL</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155724</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - MACHINE-LEARNING PREDICTION MODEL FOR PERSONALIZED URINARY TRACT INFECTION CARE IN CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>160000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BROWN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>CASHIER OFFICE BOX 1997 69 BROWN</AddressLine1Txt>
            <AddressLine2Txt>STREET 2ND FLOOR</AddressLine2Txt>
            <CityNm>PROVIDENCE</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>02912</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DEVELOPMENT OF A HIGH EFFICACY NON-CAPSID NOROVIRUS VACCINE</GrantOrContributionPurposeTxt>
          <Amt>160000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DECIPHERING MECHANISMS LINKING CHILDHOOD VIRAL INFECTION AND ASTHMA DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>160000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORCESTER POLYTECHNIC INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O TD BANK 370 MAIN ST</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01608</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - ROLE OF HETEROTRIMERIC G PROTEINS IN CILIA ASSEMBLY AND PATHOGENESIS OF NEURODEVELOPMENTAL DISORDERS</GrantOrContributionPurposeTxt>
          <Amt>160000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA MERRILL LYNCH</AddressLine1Txt>
            <AddressLine2Txt>100 WEST 33RD STREET</AddressLine2Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DIAGNOSIS OF PEDIATRIC MALIGNANCIES USING DEVELOPMENTAL MAPPING AND MACHINE LEARNING</GrantOrContributionPurposeTxt>
          <Amt>160000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>RHODE ISLAND HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>LIFESPAN OFFICE OF RESEARCH GRANTS</AddressLine1Txt>
            <AddressLine2Txt>CONTRACTS 167 POINT STREET BOX 42 C</AddressLine2Txt>
            <CityNm>PROVIDENCE</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>029034771</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>SUPPLEMENTAL FUNDING ASSISTANCE DUE TO COVID IMPACTS, FOR PRIOR CHILD HEALTH RESEARCH AWARD - EVALUATION OF POST-TUBERCULOSIS LUNG FUNCTION IN ADOLESCENTS</GrantOrContributionPurposeTxt>
          <Amt>24750</Amt>
        </GrantOrContributionPdDurYrGrp>
        <TotalGrantOrContriPdDurYrAmt>2662000</TotalGrantOrContriPdDurYrAmt>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>25 SHATTUCK ST</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02115</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHARLES AWARD [CHARLES H. HOOD ALUMNI RECOGNITION FOR LEADERSHIP, EXCELLENCE AND SERVICE] - PRESENTED TO DR. ISAAC KOHANE, MD, PHD AT FOUNDATION'S 85TH ANNIVERSARY EVENT</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>TRUSTEES OF DARTMOUTH COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>OFFICE OF SPONSORED PROJECTS 11</AddressLine1Txt>
            <AddressLine2Txt>ROPE FERRY ROAD</AddressLine2Txt>
            <CityNm>HANOVER</CityNm>
            <StateAbbreviationCd>NH</StateAbbreviationCd>
            <ZIPCd>037551421</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>MAJOR GRANT - DECREASING HARMS AND IMPROVING CHILD HEALTH: AN INTERVENTION TO REDUCE INAPPROPRIATE USE OF ANTIPSYCHOTICS AND POLYPHARMACY</GrantOrContributionPurposeTxt>
          <Amt>70250</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 222 BROADWAY ST</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10038</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - THE ROLE OF MARCO IN PEDIATRIC CANCER</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTS INSTITUTE OF TECHNOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - THE ROLE OF AIRWAY NEURONS IN CHILDHOOD ASTHMA</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DEVELOPING A BROADLY APPLICABLE THERAPEUTIC STRATEGY TO REVERSE SYMPTOMS OF NEURODEVELOPMENTAL DISORDERS</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>PO BOX 208239</AddressLine1Txt>
            <CityNm>NEW HAVEN</CityNm>
            <StateAbbreviationCd>CT</StateAbbreviationCd>
            <ZIPCd>065208239</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - NEURAL MARKERS OF CHRONIC, PERSISTENT PEDIATRIC IRRITABILITY</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BRIGHAM AND WOMEN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - SPATIAL MAPPING OF MALIGNANT SUBPOPULATIONS ENABLING NEURON-GLIOMA CIRCUIT INTERACTIONS IN DIPG</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DISSECTING IMMUNE-STROMAL INTERACTIONS TO DISCOVER NOVEL STRATEGY TO MODULATE INFLAMMATION</GrantOrContributionPurposeTxt>
          <Amt>82500</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - THE ROLE AND MECHANISM OF MAKORIN RING FINGER PROTEIN 3 IN CHILDREN WITH DELAYED PUBERTY</GrantOrContributionPurposeTxt>
          <Amt>40000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BOSTON CHILDREN'S HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 1295 BOYLSTON</AddressLine1Txt>
            <AddressLine2Txt>STREET 4TH FL</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>022155724</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - MACHINE-LEARNING PREDICTION MODEL FOR PERSONALIZED URINARY TRACT INFECTION CARE IN CHILDREN</GrantOrContributionPurposeTxt>
          <Amt>40000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BROWN UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>CASHIER OFFICE BOX 1997 69 BROWN</AddressLine1Txt>
            <AddressLine2Txt>STREET 2ND FLOOR</AddressLine2Txt>
            <CityNm>PROVIDENCE</CityNm>
            <StateAbbreviationCd>RI</StateAbbreviationCd>
            <ZIPCd>02912</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DEVELOPMENT OF A HIGH EFFICACY NON-CAPSID NOROVIRUS VACCINE</GrantOrContributionPurposeTxt>
          <Amt>40000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HARVARD MEDICAL SCHOOL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA 100 FEDERAL</AddressLine1Txt>
            <AddressLine2Txt>STREET</AddressLine2Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02110</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DECIPHERING MECHANISMS LINKING CHILDHOOD VIRAL INFECTION AND ASTHMA DEVELOPMENT</GrantOrContributionPurposeTxt>
          <Amt>40000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>WORCESTER POLYTECHNIC INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O TD BANK 370 MAIN ST</AddressLine1Txt>
            <CityNm>WORCESTER</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>01608</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - ROLE OF HETEROTRIMERIC G PROTEINS IN CILIA ASSEMBLY AND PATHOGENESIS OF NEURODEVELOPMENTAL DISORDERS</GrantOrContributionPurposeTxt>
          <Amt>40000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>C/O BANK OF AMERICA MERRILL LYNCH</AddressLine1Txt>
            <AddressLine2Txt>100 WEST 33RD STREET</AddressLine2Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10001</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>CHILD HEALTH RESEARCH AWARD - DIAGNOSIS OF PEDIATRIC MALIGNANCIES USING DEVELOPMENTAL MAPPING AND MACHINE LEARNING</GrantOrContributionPurposeTxt>
          <Amt>40000</Amt>
        </GrantOrContriApprvForFutGrp>
        <TotalGrantOrContriApprvFutAmt>905250</TotalGrantOrContriApprvFutAmt>
      </SupplementaryInformationGrp>
      <AnalysisIncomeProducingActyGrp>
        <DividendsAndInterestFromSecDtl>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>1335080</ExclusionAmt>
        </DividendsAndInterestFromSecDtl>
        <GainSalesAstOthThanInvntryGrp>
          <ExclusionCd>18</ExclusionCd>
          <ExclusionAmt>612940</ExclusionAmt>
        </GainSalesAstOthThanInvntryGrp>
        <OtherRevenueDescribedGrp>
          <Desc>RETURNED GRANT FUNDS</Desc>
          <RelatedOrExemptFunctionIncmAmt>31917</RelatedOrExemptFunctionIncmAmt>
        </OtherRevenueDescribedGrp>
        <OtherRevenueDescribedGrp>
          <Desc>OTHER INVESTMENT INCOME</Desc>
          <RelatedOrExemptFunctionIncmAmt>5343</RelatedOrExemptFunctionIncmAmt>
        </OtherRevenueDescribedGrp>
        <SubtotalsIncmProducingActyGrp>
          <UnrelatedBusinessTaxblIncmAmt>0</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionAmt>1948020</ExclusionAmt>
          <RelatedOrExemptFunctionIncmAmt>37260</RelatedOrExemptFunctionIncmAmt>
        </SubtotalsIncmProducingActyGrp>
        <TotalIncomeProducingActyAmt>1985280</TotalIncomeProducingActyAmt>
      </AnalysisIncomeProducingActyGrp>
      <RlnOfActyToAccomOfExmptPrpsGrp>
        <RlnOfActyToAccomOfExmptPrpsGrp>
          <LineNumberTxt>11A</LineNumberTxt>
          <RelationshipStatementTxt>EXCESS FUNDS RETURNED FROM GRANTS PREVIOUSLY PAID OUT.</RelationshipStatementTxt>
        </RlnOfActyToAccomOfExmptPrpsGrp>
        <RlnOfActyToAccomOfExmptPrpsGrp>
          <LineNumberTxt>11B</LineNumberTxt>
          <RelationshipStatementTxt>SETTLEMENT PROCEEDS ON INVESTMENTS</RelationshipStatementTxt>
        </RlnOfActyToAccomOfExmptPrpsGrp>
      </RlnOfActyToAccomOfExmptPrpsGrp>
      <TrnsfrTransRlnNonchrtblEOGrp>
        <TrnsfrOfCashToNonchrtblEOInd>0</TrnsfrOfCashToNonchrtblEOInd>
        <TrnsfrOtherAssetNonchrtblEOInd>0</TrnsfrOtherAssetNonchrtblEOInd>
        <SalesOrExchangesOfAssetsInd>0</SalesOrExchangesOfAssetsInd>
        <PurchaseOfAssetsNonchrtblEOInd>0</PurchaseOfAssetsNonchrtblEOInd>
        <RentalOfFacilitiesOthAssetsInd>0</RentalOfFacilitiesOthAssetsInd>
        <ReimbursementArrangementsInd>0</ReimbursementArrangementsInd>
        <LoansOrLoanGuaranteesInd>0</LoansOrLoanGuaranteesInd>
        <PerformanceOfServicesEtcInd>0</PerformanceOfServicesEtcInd>
        <SharingOfFacilitiesEtcInd>0</SharingOfFacilitiesEtcInd>
        <RelationshipsNonchrtblEOInd>0</RelationshipsNonchrtblEOInd>
      </TrnsfrTransRlnNonchrtblEOGrp>
    </IRS990PF>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <GeneralRuleInd>X</GeneralRuleInd>
      <ContributorInformationGrp>
        <ContributorNum>1</ContributorNum>
        <ContributorPersonNm>ESTATE OF JUDITH HOOD</ContributorPersonNm>
        <ContributorUSAddress>
          <AddressLine1Txt>BANK OF AMERICA 1025 MAIN STREET MA</AddressLine1Txt>
          <CityNm>WALTHAM</CityNm>
          <StateAbbreviationCd>ME</StateAbbreviationCd>
          <ZIPCd>02451</ZIPCd>
        </ContributorUSAddress>
        <TotalContributionsAmt>1029761</TotalContributionsAmt>
        <PersonContributionInd>X</PersonContributionInd>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <AccountingFeesSchedule documentId="RetDoc2002200001">
      <AccountingFeesDetail>
        <CategoryTxt>ACCOUNTING &amp; TAX PREPARATION FEES</CategoryTxt>
        <Amt>26003</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>26003</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
    </AccountingFeesSchedule>
    <AllOthProgRltdInvestmentsSch documentId="RetDoc2063500001">
      <AllOtherProgramRelatedInvstGrp>
        <Desc>SMOLTAP - PROVIDENCE, RI SERIES SEED PREFERRED STOCK INVESTMENT</Desc>
        <Amt>99997</Amt>
      </AllOtherProgramRelatedInvstGrp>
      <AllOtherProgramRelatedInvstGrp>
        <Desc>NOVONATE - SOUTH SAN FRANCISCO, CA SAFE - SIMPLE AGREEMENT FOR FUTURE EQUITY</Desc>
        <Amt>150000</Amt>
      </AllOtherProgramRelatedInvstGrp>
      <AllOtherProgramRelatedInvstGrp>
        <Desc>BIOROSA TECHNOLOGIES - BELMONT, MA UNSECURED CONVERTIBLE PROMISSORY NOTE</Desc>
        <Amt>100000</Amt>
      </AllOtherProgramRelatedInvstGrp>
    </AllOthProgRltdInvestmentsSch>
    <ExpenditureResponsibilityStmt documentId="RetDoc2118100001">
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NONINVASIX INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1700 THE STRAND SUITE 1200</AddressLine1Txt>
          <CityNm>GALVESTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77555</ZIPCd>
        </USAddress>
        <GrantDt>2017-07-27</GrantDt>
        <GrantAmt>7000</GrantAmt>
        <PurposeOfGrantTxt>TO FUND NONINVASIX'S PARTICIPATION IN THE PHILIPS' MATERNAL AND INFANT HEALTHWORKS START-UP PROGRAM.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>7000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 4/28/2023, 5/25/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BREEGI SCIENTIFIC INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>120 BEDFORD ROAD</AddressLine1Txt>
          <CityNm>WOBURN</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01801</ZIPCd>
        </USAddress>
        <GrantDt>2017-06-26</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>THE FUNDS WILL BE USED TO CONDUCT A THOROUGH CLINICAL ASSESSMENT OF BSI'S NOVEL NEONATAL INTENSIVE CARE INCUBATOR "(NICI)" IN HONDURAS AND ZAMBIA AND TO AID THE COMMERCIALIZATION EFFORTS OF THIS LIFE-SAVING MEDICAL DEVICE, THEREBY LESSENING THE BURDEN OF THE GOVERNMENT AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/13/2022, 9/13/2022, 1/5/2023, 8/24/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2021-08-02</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH BREEGI SCIENTIFIC, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NONINVASIX INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1700 THE STRAND SUITE 1200</AddressLine1Txt>
          <CityNm>GALVESTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77555</ZIPCd>
        </USAddress>
        <GrantDt>2015-12-30</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS -4/28/2023, 5/25/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ALDATU BIOSCIENCES INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>C/O ARSENAL LAB SPACE 201 DEXTER</AddressLine1Txt>
          <AddressLine2Txt>AVE</AddressLine2Txt>
          <CityNm>WATERTOWN</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02472</ZIPCd>
        </USAddress>
        <GrantDt>2016-02-23</GrantDt>
        <GrantAmt>100000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE USE AND DEVELOPMENT OF A SIMPLE, RAPID, THERMOSTABLE KIT THAT IDENTIFIES CLINICALLY ACTIONABLE HIV MUTATIONS FOUND IN PATIENTS FAILING A FIRST-LINE DRUG REGIMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>100000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 6/14/2022, 12/1/2022, 5/26/2023, 6/12/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ALDATU BIOSCIENCES, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NONINVASIXINC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1700 THE STRAND SUITE 1200</AddressLine1Txt>
          <CityNm>GALVESTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77555</ZIPCd>
        </USAddress>
        <GrantDt>2016-07-27</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE USE AND DEVELOPMENT OF THE COMPANY'S PEDIATRIC BRAIN OXYGENATION MONITORING SYSTEM, WHICH HAS THE POTENTIAL TO MORE ACCURATELY ASSESS THE RISK OF BRAIN HYPOXIA IN FETUSES AND NEONATES, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 4/28/2023, 5/25/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2017-12-15</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NONINVASIX, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>THINKMD INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>166 MAIN STREET</AddressLine1Txt>
          <CityNm>BURLINGTON</CityNm>
          <StateAbbreviationCd>VT</StateAbbreviationCd>
          <ZIPCd>05401</ZIPCd>
        </USAddress>
        <GrantDt>2018-05-17</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>FOR DEVELOPING INTEGRATED CLINICAL ASSESSMENT AND DATA ANALYTICS PLATFORMS AND OTHER DERIVATIVE PRODUCTS THAT TRANSFORM POINT-OF-CARE MEDICINE BY PUTTING VALIDATED CLINICAL ASSESSMENT CAPABILITY AND INCREASED HEALTHCARE KNOWLEDGE INTO THE HANDS OF CLINICALLY UNTRAINED HEALTHCARE PROFESSIONALS AND FAMILIES THEREBY LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 5/4/22, 7/31/22, 11/15/22, 2/20/23, 5/16/23, 6/2/23, 7/5/23</DatesOfReportsByGranteeTxt>
        <VerificationDt>2019-02-11</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH THINKMD, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>PRAPELA LLC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2 MAIN STREET</AddressLine1Txt>
          <CityNm>BIDDEFORD</CityNm>
          <StateAbbreviationCd>ME</StateAbbreviationCd>
          <ZIPCd>04005</ZIPCd>
        </USAddress>
        <GrantDt>2018-07-02</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF THE COMPANY'S SLEEP TECHNOLOGY PRODUCTS FOR IMPROVING THE HEALTH OF INFANTS WHO COULD BENEFIT FROM WITHDRAWAL TREATMENT AND POST-WITHDRAWAL SUPPORT OF NEONATAL ABSTINENCE SYNDROME ("NAS") A CONDITION CAUSED BY THE PRENATAL USE OF OPIOIDS OR OTHER DRUGS BY PREGNANT WOMEN, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE, LESSENING THE BURDEN OF THE GOVERNMENT, AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 5/6/2022, 3/1/2023, 6/22/2023, 7/10/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2020-09-10</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH PRAPELA, LLC MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>STINGRAY THERAPEUTICS</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>2450 HOLCOMBE BLVD SUITE X</AddressLine1Txt>
          <CityNm>HOUSTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77021</ZIPCd>
        </USAddress>
        <GrantDt>2019-04-08</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>FUNDS WILL BE USED FOR PRECLINICAL WORK FOCUSED ON PEDIATRIC BRAIN CANCERS, INCLUDING WORK TO DEVELOP PRECLINICAL MODELS AND TO TEST COMPOUNDS AGAINST MEDULLOBLASTOMA, AN ULTRA-RARE PEDIATRIC BRAIN CANCER, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 2/17/22, 5/11/22, 9/30/2022, 3/2/2023, 5/25/2023, 6/29/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2021-05-18</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH STINGRAY THERAPEUTICS MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY.</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>149 MEDICAL INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>1173 MAIN STREET</AddressLine1Txt>
          <CityNm>BOLTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>01740</ZIPCd>
        </USAddress>
        <GrantDt>2020-04-17</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PRE-COMMERCIALIZATION DEVELOPMENT OF A MONITOR THAT MEASURES REAL-TIME BRAIN HEMODYNAMICS AND METABOLISM IN PRETERM NEWBORNS, IN AN ATTEMPT TO CHANGE THE STANDARD OF CARE BY IMPROVING LIVES, REDUCING MEDICAL ERRORS, AND REDUCING OVERALL HEALTHCARE COSTS, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 2/17/2022, 4/6/2022, 6/10/2022,8/25/2022, 9/22/2022, 8/16/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2022-06-10</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH 149 MEDICAL, INC. ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ANIDA PHARMA INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>155 BROOKLINE STREET SUITE 005</AddressLine1Txt>
          <CityNm>CAMBRIDGE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02139</ZIPCd>
        </USAddress>
        <GrantDt>2020-12-21</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PRECLINICAL DEVELOPMENT OF A PREVENTATIVE TREATMENT FOR RETINOPATHY OF PREMATURITY, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT 6/11/2022, 8/29/2022, 7/21/2023, 8/23/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-07-21</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ANIDA PHARMA, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BIOROSA TECHNOLOGIES INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>63 BAKER STREET</AddressLine1Txt>
          <CityNm>BELMONT</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02478</ZIPCd>
        </USAddress>
        <GrantDt>2020-07-15</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF A BLOOD-BASED STANDARD-OF-CARE DIAGNOSTIC FOR AUTISM SPECTRUM DISORDERS ("ASD") THAT IS INTENDED TO LEAD TO EARLIER DETECTION OF ASD THAN IS CURRENTLY AVAILABLE, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>150000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 1/27/2022, 5/16/2022, 6/22/2022, 12/11/2022, 8/14/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2021-07-16</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH BIOROSA TECHNOLOGIES, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>MESENTECH INC</BusinessNameLine1Txt>
        </BusinessName>
        <ForeignAddress>
          <AddressLine1Txt>2222 HEALTH SCIENCES RD</AddressLine1Txt>
          <CityNm>VANCOUVER</CityNm>
          <ProvinceOrStateNm>BRITISH COLUMBIA</ProvinceOrStateNm>
          <CountryCd>CA</CountryCd>
          <ForeignPostalCd>V6T2B9</ForeignPostalCd>
        </ForeignAddress>
        <GrantDt>2020-11-02</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE ADVANCEMENT OF SCIENCE AND PROMOTION OF HEALTH THROUGH THE PRECLINICAL RESEARCH OF ANABOLIC BONE THERAPEUTICS THAT CAN INCREASE BONE MASS TO STRENGTHEN THE SKELETON AND THE DEVELOPMENT OF A DRUG DELIVERY SYSTEM TO BE INITIALLY APPLIED TO TWO PEDIATRIC RARE DISEASES: OSTEOGENESIS IMPERFECTA AND DUCHENNE MUSCULAR DYSTROPHY.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 2/10/2022, 8/26/2022, 12/19/2022, 7/3/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2022-08-26</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH MESENTECH, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>ARGUS COGNITIVE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>DARTMOUTH REGIONAL TECHNICAL CENTER</AddressLine1Txt>
          <AddressLine2Txt>16 CAVENDISH</AddressLine2Txt>
          <CityNm>LEBANON</CityNm>
          <StateAbbreviationCd>NH</StateAbbreviationCd>
          <ZIPCd>03766</ZIPCd>
        </USAddress>
        <GrantDt>2021-05-10</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT AND CLINICAL TESTING OF THE CORPORATION'S CLINICAL DECISION SUPPORT SOFTWARE FOR USE IN PEDIATRIC INDICATIONS, INCLUDING AUTISM AND PEDIATRIC CARDIOLOGY, THEREBY SUPPORTING RELIEF OF THE POOR, DISTRESSED AND UNDERPRIVILEGED AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>250000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 6/24/2022, 9/29/2022, 11/30/2022, 8/23/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-08-23</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH ARGUS COGNITIVE, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NICOLETTE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>100 W BROADWAY SUITE 3000</AddressLine1Txt>
          <CityNm>LONG BEACH</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>90802</ZIPCd>
        </USAddress>
        <GrantDt>2021-12-23</GrantDt>
        <GrantAmt>200000</GrantAmt>
        <PurposeOfGrantTxt>TO DEVELOP AND TEST A TABLET-BASED APPLICATION THAT TRANSLATES DATA PULLED FROM A BABY'S ELECTRONIC MEDICAL RECORD INTO EASILY UNDERSTOOD, SIMPLE SENTENCES COMPLEMENTED BY VISUAL AIDS, SUCH AS GRAPHS AND CHARTS, FOR THE BENEFIT OF THE PUBLIC, INCLUDING PARENTS, IN AN ATTEMPT TO CHANGE THE STANDARD OF CARE BY IMPROVING LIVES, REDUCING MEDICAL ERRORS, AND REDUCING OVERALL HEALTHCARE COSTS.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>194650</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 1/3/2022, 5/2/2022, 7/26/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-07-26</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NICOLETTE, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>SMOLTAP INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>150 CHESTNUT STREET SUITE C</AddressLine1Txt>
          <CityNm>PROVIDENCE</CityNm>
          <StateAbbreviationCd>RI</StateAbbreviationCd>
          <ZIPCd>02903</ZIPCd>
        </USAddress>
        <GrantDt>2022-07-25</GrantDt>
        <GrantAmt>99997</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO DEVELOP A NOVEL DEVICE WHICH HOLDS AN INFANT STABLE DURING THE LUMBER PUNCTURE PROCEDURE WHEN ADMINISTERING A SPINAL TAP TO DIAGNOSE MENINGITIS IN IN FEBRILE INFANTS UP TO FOUR WEEKS OLD.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>99997</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 8/30/2022, 2/15/2023, 5/30/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-05-30</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH SMOLTAP, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>NOVONATE INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>395 OYSTER POINT BLVD SUITE 501</AddressLine1Txt>
          <CityNm>SOUTH SAN FRANCISCO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94080</ZIPCd>
        </USAddress>
        <GrantDt>2022-08-03</GrantDt>
        <GrantAmt>150000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE PERFORMANCE OF SCIENTIFIC RESEARCH TO BENEFIT THE PUBLIC BY DEVELOPING MEDICAL DEVICES FOR PATIENTS IN THE NEONATAL INTENSIVE CARE UNIT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>123600</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 8/9/2022, 8/12/2022, 7/25/2023, 7/27/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-07-27</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH NOVONATE, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>DECK THERAPEUTICS INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>8 HARVARD LANE</AddressLine1Txt>
          <CityNm>HASTINGS ON HUDSON</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10706</ZIPCd>
        </USAddress>
        <GrantDt>2022-10-12</GrantDt>
        <GrantAmt>200000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF SEMI-SYNTHETIC OMEGA-3 COMPOUNDS THAT BLOCK MULTIPLE CELL-DEATH PATHWAYS INDUCED BY HYPOXIC-ISCHEMIC INJURY IN NEONATES.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>51666</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 10/2022, 3/29/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-03-29</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH DECK THERAPEUTICS, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>INKSPACE IMAGING INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>5635 W LAS POSITAS BLVD STE 403/404</AddressLine1Txt>
          <CityNm>PLEASANTON</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94588</ZIPCd>
        </USAddress>
        <GrantDt>2022-10-20</GrantDt>
        <GrantAmt>250000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF FLEXIBLE, LIGHTWEIGHT, LOW COST MRI COILS DESIGNED SPECIFICALLY FOR PEDIATRIC PATIENTS, WHILE ALSO IMPROVING IMAGE RESOLUTION AND REDUCING MRI FAILURE RATES.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>64848</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORT - 12/23/2022, 6/5/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-06-05</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH INKSPACE IMAGING, INC. MANAGEMENT ON A REGULAR BASIS AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
      <ExpenditureResponsibilityGrp>
        <BusinessName>
          <BusinessNameLine1Txt>BIOROSA TECHNOLOGIES INC</BusinessNameLine1Txt>
        </BusinessName>
        <USAddress>
          <AddressLine1Txt>63 BAKER STREET</AddressLine1Txt>
          <CityNm>BELMONT</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02478</ZIPCd>
        </USAddress>
        <GrantDt>2022-11-15</GrantDt>
        <GrantAmt>100000</GrantAmt>
        <PurposeOfGrantTxt>TO SUPPORT THE DEVELOPMENT OF A BLOOD-BASED STANDARD-OF-CARE DIAGNOSTIC FOR AUTISM SPECTRUM DISORDERS ("ASD") THAT IS INTENDED TO LEAD TO EARLIER DETECTION OF ASD THAN IS CURRENTLY AVAILABLE, THEREBY SUPPORTING THE ADVANCEMENT OF SCIENCE AND LESSENING THE BURDEN OF THE GOVERNMENT.</PurposeOfGrantTxt>
        <ExpendedByGranteeAmt>100000</ExpendedByGranteeAmt>
        <AnyDiversionByGranteeTxt>NONE, SEE BELOW</AnyDiversionByGranteeTxt>
        <DatesOfReportsByGranteeTxt>PRI REPORTS - 1/27/2022, 5/16/2022, 6/22/2022, 12/11/2022, 8/14/2023</DatesOfReportsByGranteeTxt>
        <VerificationDt>2023-08-14</VerificationDt>
        <ResultsOfVerificationTxt>THE TRUSTEES MEET WITH BIOROSA TECHNOLOGIES, INC. MANAGEMENT ON A REGULAR BAS1S, ATTEND BOARD MEETINGS AS AN OBSERVER AND REVIEW THE PRI REPORTS AND FINANCIALS. TO THE TRUSTEES KNOWLEDGE, THE GRANTEE HAS NOT DIVERTED ANY OF THE FUNDS FROM THE PURPOSE OF THE GRANT. NO ADDITIONAL FOLLOW UP DEEMED NECESSARY</ResultsOfVerificationTxt>
      </ExpenditureResponsibilityGrp>
    </ExpenditureResponsibilityStmt>
    <InvestmentsCorpBondsSchedule documentId="RetDoc2044400001">
      <InvestmentsCorporateBondsGrp>
        <BondNm>FIXED INCOME</BondNm>
        <EOYBookValueAmt>13292160</EOYBookValueAmt>
        <EOYFMVAmt>13292160</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
    </InvestmentsCorpBondsSchedule>
    <InvestmentsCorpStockSchedule documentId="RetDoc2018900001">
      <InvestmentsCorporateStockGrp>
        <StockNm>DOMESTIC EQUITIES</StockNm>
        <EOYBookValueAmt>25060411</EOYBookValueAmt>
        <EOYFMVAmt>25060411</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
      <InvestmentsCorporateStockGrp>
        <StockNm>FOREIGN SECURITIES</StockNm>
        <EOYBookValueAmt>9777340</EOYBookValueAmt>
        <EOYFMVAmt>9777340</EOYFMVAmt>
      </InvestmentsCorporateStockGrp>
    </InvestmentsCorpStockSchedule>
    <InvestmentsOtherSchedule2 documentId="RetDoc2018100001">
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>REAL ESTATE</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>2586626</BookValueAmt>
        <EOYFMVAmt>2586626</EOYFMVAmt>
      </InvestmentsOtherGrp>
      <InvestmentsOtherGrp>
        <CategoryOrItemTxt>ALTERNATIVE INVESTMENTS</CategoryOrItemTxt>
        <ListedAtCostOrFMVCd>FMV</ListedAtCostOrFMVCd>
        <BookValueAmt>12208432</BookValueAmt>
        <EOYFMVAmt>12208432</EOYFMVAmt>
      </InvestmentsOtherGrp>
    </InvestmentsOtherSchedule2>
    <LegalFeesSchedule documentId="RetDoc2002100001">
      <LegalFeesGrp>
        <CategoryTxt>LEGAL EXPENSES</CategoryTxt>
        <LegalFeesAmt>30210</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>30210</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
    </LegalFeesSchedule>
    <OtherAssetsSchedule documentId="RetDoc2046600001">
      <OtherAssetsScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENTS</Desc>
        <BOYBookValueAmt>2569964</BOYBookValueAmt>
        <EOYBookValueAmt>3369961</EOYBookValueAmt>
        <EOYFMVAmt>3369961</EOYFMVAmt>
      </OtherAssetsScheduleGrp>
    </OtherAssetsSchedule>
    <OtherDecreasesSchedule documentId="RetDoc2049800001">
      <OtherDecreasesDetail>
        <Desc>UNREALIZED LOSSES</Desc>
        <Amt>11863391</Amt>
      </OtherDecreasesDetail>
      <OtherDecreasesDetail>
        <Desc>LOSS ON ALTERNATIVE INVESTMENTS</Desc>
        <Amt>109265</Amt>
      </OtherDecreasesDetail>
    </OtherDecreasesSchedule>
    <OtherExpensesSchedule documentId="RetDoc2003200001">
      <OtherExpensesScheduleGrp>
        <Desc>FILING FEES</Desc>
        <RevenueAndExpensesPerBooksAmt>539</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>539</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>MISCELLANEOUS EXPENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>3968</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>3968</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>HRIA ADMINISTRATIVE COSTS</Desc>
        <RevenueAndExpensesPerBooksAmt>199378</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>199378</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>PROGRAM RELATED INVESTMENT ADMINISTRATIVE COSTS</Desc>
        <RevenueAndExpensesPerBooksAmt>18132</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>18132</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>MARKETING</Desc>
        <RevenueAndExpensesPerBooksAmt>14214</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>14214</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>HONORARIA</Desc>
        <RevenueAndExpensesPerBooksAmt>13025</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>13025</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>SCIENTIFIC ADVISORS</Desc>
        <RevenueAndExpensesPerBooksAmt>35190</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>35190</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>EVENT EXPENSE</Desc>
        <RevenueAndExpensesPerBooksAmt>112808</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>112808</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>OFFICERS' INSURANCE</Desc>
        <RevenueAndExpensesPerBooksAmt>947</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>947</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
    </OtherExpensesSchedule>
    <OtherIncomeSchedule2 documentId="RetDoc2001500001">
      <OtherIncomeDetail>
        <Desc>RETURNED GRANT FUNDS</Desc>
        <RevenueAndExpensesPerBooksAmt>31917</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>31917</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
      <OtherIncomeDetail>
        <Desc>OTHER INVESTMENT INCOME</Desc>
        <RevenueAndExpensesPerBooksAmt>5343</RevenueAndExpensesPerBooksAmt>
        <AdjustedNetIncomeAmt>5343</AdjustedNetIncomeAmt>
      </OtherIncomeDetail>
    </OtherIncomeSchedule2>
    <OtherProfessionalFeesSchedule documentId="RetDoc2002300001">
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT FEES - US TRUST</CategoryTxt>
        <Amt>28585</Amt>
        <NetInvestmentIncomeAmt>14292</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>14293</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
      <OtherProfessionalFeesDetail>
        <CategoryTxt>INVESTMENT CONSULTING</CategoryTxt>
        <Amt>75000</Amt>
        <NetInvestmentIncomeAmt>75000</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </OtherProfessionalFeesDetail>
    </OtherProfessionalFeesSchedule>
    <TaxesSchedule documentId="RetDoc2002500001">
      <TaxesDetail>
        <CategoryTxt>FEDERAL EXCISE TAXES FOR 2022</CategoryTxt>
        <Amt>57779</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>MA FORM PC FILING FEE FOR 2021</CategoryTxt>
        <Amt>500</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>500</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
      <TaxesDetail>
        <CategoryTxt>FOREIGN TAXES</CategoryTxt>
        <Amt>25400</Amt>
        <NetInvestmentIncomeAmt>25400</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>0</DisbursementsCharitablePrpsAmt>
      </TaxesDetail>
    </TaxesSchedule>
  </ReturnData>
</Return>
